Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics (Nasdaq: KPTI) has granted 10,500 restricted stock units (RSUs) to three newly-hired employees as of October 31, 2024. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and will vest over three years, with 33 1/3% vesting annually. The grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of employment termination following a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 5, 2024. The management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day. The presentation will include financial results and company updates, with dial-in numbers provided for both local and international participants. A live webcast with slides will be available on the company's investor website, with an archived version accessible approximately two hours after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed promising results with 79% of patients achieving SVR35 and an average Abs-TSS improvement of 18.5 points at week 24 when combining selinexor with ruxolitinib, compared to historical data showing less than 50% SVR35 achievement with JAK inhibitor monotherapy.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced a conference call and webcast scheduled for October 31, 2024, at 8:00 a.m. ET. The event will feature leading myelofibrosis experts Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai. They will provide a favorable study design update on the company's pivotal Phase 3 SENTRY study in JAKi naive myelofibrosis.
The conference call will be accessible via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live webcast with slides will be available on the company's investor website, with an archived version available approximately two hours after the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focusing on novel cancer therapies, has announced the granting of 17,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted on September 30, 2024, under the company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSU awards will vest over a three-year period, with 33 1/3% of the shares vesting on each anniversary of the Grant Date, subject to continued employment. In the event of a "change in control event" followed by termination for "good reason" or without "cause" within one year, the RSUs will become immediately exercisable in full.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focusing on novel cancer therapies, has announced the granting of 22,050 restricted stock units (RSUs) to five newly-hired employees. These RSU awards, granted on August 31, 2024, are part of the company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued employment. In case of a 'change in control event' followed by termination under specific conditions within a year, the RSUs will become fully exercisable.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company specializing in novel cancer therapies, has announced its participation in two upcoming investor conferences in September 2024:
- H.C. Wainwright 26th Annual Global Investment Conference on September 10, featuring a podium presentation at 9:00 a.m. ET
- Baird 2024 Global Healthcare Conference on September 11, with a fireside chat at 10:50 a.m. ET
Live webcasts and slides will be available on the company's website. Karyopharm is known for its oral compound XPOVIO® (selinexor), an XPO1 inhibitor approved in the U.S. for three oncology indications and in other countries as NEXPOVIO®. The company focuses on high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported financial results for Q2 2024, achieving total revenue of $42.8 million and U.S. XPOVIO® net product revenue of $28.0 million. The company highlighted:
1. Updated clinical results from the SIENDO study showing promising PFS in endometrial cancer subgroups.
2. Completion of refinancing transactions extending debt maturities to 2028 and 2029.
3. Raised lower end of 2024 revenue guidance to $145.0-$160.0 million.
4. Lowered 2024 R&D and SG&A expense guidance to $250.0-$265.0 million.
5. Reported net income of $23.8 million for Q2 2024.
6. Cash position of $152.5 million as of June 30, 2024.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 14,000 restricted stock units (RSUs) to four newly-hired employees. These RSU awards, granted on July 31, 2024, are part of the Company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued employment. In the event of a 'change in control,' the RSUs may become fully exercisable if the employee's employment is terminated under specific conditions within one year of the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024. The company's management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the financial results and provide company updates.
Investors and interested parties can access the conference call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start time. A live audio webcast of the call, along with accompanying slides, will be available on the company's website under the 'Events & Presentations' section. An archived version of the webcast will be accessible approximately two hours after the event.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
